ENDMC
MCID: END057
MIFTS: 71

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 57 12 72 36 13 54 6 15
Endometrial Carcinoma 12 29 54 6 15 17 70
Endometrial Neoplasm 12 29 6 17
Malignant Neoplasm of Endometrium 12 70
Carcinoma, Endometrioid 44 70
Endometrioid Carcinoma 12 17
Endometrial Neoplasms 44 70
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 57
Endometrial Carcinoma, Somatic 57
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 57
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Carcinoma Endometrioid 54
Uterine Corpus Cancer 70
Tumor of Endometrium 12
Endometrial Cancers 15
Cancer, Endometrial 39
Endometrial Ca 12
Endmc 72

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
often seen in cancer predisposition syndromes such as hereditary nonpolyposis colorectal cancer (see )


HPO:

31
endometrial cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:1380 DOID:2871
OMIM® 57 608089
KEGG 36 H00026
ICD10 32 C54.1
MedGen 41 C0476089
SNOMED-CT via HPO 68 124975008 254878006 263681008
UMLS 70 C0007103 C0014170 C0206687 more

Summaries for Endometrial Cancer

KEGG : 36 Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and endometrial adenocarcinoma. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Fluorodeoxyglucose F18 and Histamine have been mentioned in the context of this disorder. Affiliated tissues include tissues lining the uterus, breast and lymph node, and related phenotypes are endometrial carcinoma and neoplasm

Disease Ontology : 12 A uterine cancer that is located in tissues lining the uterus.

UniProtKB/Swiss-Prot : 72 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

Wikipedia : 73 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

More information from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 691)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.2 PTEN MUTYH MSH6 MSH3 MLH3
2 endometrial adenocarcinoma 32.6 PTEN FGFR2 CDH1
3 colorectal cancer, hereditary nonpolyposis, type 5 32.4 MUTYH MSH6
4 cowden syndrome 1 32.4 PTEN MUTYH MSH6
5 cowden syndrome 31.6 PTEN MUTYH MSH6 MSH3
6 ovarian cancer 31.5 UCA1 TUG1 PTEN NEAT1 MUTYH MSH6
7 uterine carcinosarcoma 31.5 PTEN FGFR2 CDH1
8 cervical cancer 31.5 ZNRD1ASP UCA1 TUG1 PTEN NEAT1 HOTAIR
9 familial adenomatous polyposis 31.4 MUTYH MSH6 MSH3 CDH1
10 breast cancer 31.2 UCA1 TUG1 PTEN NEAT1 MUTYH MSH6
11 retinitis pigmentosa 11 31.0 UCA1 PTEN NEAT1 HOTAIR
12 colorectal cancer 31.0 UCA1 TUG1 PTEN NEAT1 MUTYH MSH6
13 bladder cancer 31.0 UCA1 TUG1 PTEN HOTAIR GAS5 FGFR2
14 kidney cancer 31.0 PTEN MIR200C HOTAIR GAS5
15 thyroid carcinoma 30.9 UCA1 PTEN NEAT1 HOTAIR GAS5 CASC2
16 familial colorectal cancer 30.9 MUTYH CDH1 AREL1
17 endometrioid ovary carcinoma 30.8 PTEN MSH6
18 bilateral breast cancer 30.8 PTEN MSH6 CDH1
19 melanoma 30.8 UCA1 PTEN MIR200C LINC-ROR HOTAIR GAS5
20 myeloma, multiple 30.8 UCA1 TUG1 PTEN HOTAIR GAS5 CCAT1
21 li-fraumeni syndrome 30.8 PTEN MUTYH MSH6 CDH1
22 muir-torre syndrome 30.7 MUTYH MSH6 MSH3 MLH3
23 bladder urothelial carcinoma 30.7 TUG1 PTEN HOTAIR GAS5 CDH1
24 colorectal adenoma 30.7 PTEN MUTYH CDH1
25 lung cancer susceptibility 3 30.7 TUG1 MIR200C LINC-ROR HOTAIR GAS5 FGFR2
26 female reproductive endometrioid cancer 30.6 PTEN MSH6
27 pancreatic ductal adenocarcinoma 30.6 UCA1 PTEN MIR200C HOTAIR CDH1
28 squamous cell carcinoma 30.6 UCA1 TUG1 PTEN NEAT1 HOTAIR FGFR2
29 osteogenic sarcoma 30.6 UCA1 TUG1 NEAT1 HOTAIR GAS5 CCAT1
30 lung squamous cell carcinoma 30.6 TUG1 PTEN FGFR2 CDH1 CCAT1
31 leukemia, acute myeloid 30.6 UCA1 TUG1 PTEN HOTAIR CDH1 CCAT1
32 colorectal adenocarcinoma 30.6 PTEN MSH6 CDH1
33 gallbladder cancer 30.5 UCA1 TUG1 LINC-ROR HOTAIR CDH1 CCAT1
34 glioma 30.5 UCA1 PTEN NEAT1 HOTAIR GAS5 FGFR2
35 gastric cancer 30.5 UCA1 TUG1 PTEN NEAT1 MUTYH MSH6
36 squamous cell carcinoma, head and neck 30.5 PTEN HOTAIR HAND2-AS1 GAS5 CDH1
37 thyroid cancer, nonmedullary, 1 30.5 NEAT1 LINC-ROR HOTAIR
38 esophageal cancer 30.5 UCA1 PTEN MIR200C LINC-ROR HOTAIR GAS5
39 high grade glioma 30.5 TUG1 PTEN NEAT1 LINC-ROR HOTAIR GAS5
40 lung cancer 30.4 ZNRD1ASP UCA1 TUG1 PTEN NEAT1 MSH3
41 pancreatic cancer 30.4 UCA1 TUG1 PTEN NEAT1 MIR200C LINC-ROR
42 renal cell carcinoma, nonpapillary 30.4 UCA1 TUG1 PTEN MIR200C LINC-ROR HOTAIR
43 attenuated familial adenomatous polyposis 30.3 MUTYH MSH6
44 oral squamous cell carcinoma 30.3 UCA1 TUG1 NEAT1 MIR200C HOTAIR CDH1
45 medulloblastoma 30.2 PTEN MSH6 HOTAIR CDH1 CCAT1
46 high-grade neuroendocrine carcinoma of the corpus uteri 11.3
47 ovarian endometrial cancer 11.2
48 polycystic ovary syndrome 11.1
49 lynch syndrome i 11.1
50 cervical endometrioid adenocarcinoma 11.1

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Human phenotypes related to Endometrial Cancer:

31
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 31 HP:0012114

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neoplasia:
endometrial cancer

Clinical features from OMIM®:

608089 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Endometrial Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 CDH1 FGFR2 MSH3 MSH6 MUTYH PTEN

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Fluorodeoxyglucose F18 Phase 4
2
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
3
Promethazine Approved, Investigational Phase 3 60-87-7 4927
4
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
8
Cetirizine Approved Phase 3 83881-51-0 2678
9
Famotidine Approved Phase 3 76824-35-6 3325
10
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
11
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
12
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
13
Lenvatinib Approved, Investigational Phase 3 417716-92-8
14
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
15
tannic acid Approved Phase 3 1401-55-4
16
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
17
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
18
Sodium citrate Approved, Investigational Phase 3 68-04-2
19
Tamoxifen Approved Phase 3 10540-29-1 2733526
20
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
21
Lenograstim Approved, Investigational Phase 3 135968-09-1
22
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
23
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
24
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
26
Cediranib Investigational Phase 3 288383-20-0 9933475
27
Maleic acid Experimental Phase 3 110-16-7 444266
28
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
29 Carotenoids Phase 3
30 DHEA (Dehydroepiandrosterone) Phase 3
31 Neurotransmitter Agents Phase 3
32
Histamine Phosphate Phase 3 51-74-1 65513
33 Antiemetics Phase 3
34 Anesthetics, Local Phase 3
35 Histamine H1 Antagonists Phase 3
36 Dermatologic Agents Phase 3
37 Histamine Antagonists Phase 3
38 Anti-Allergic Agents Phase 3
39
Isophosphamide mustard Phase 3 100427
40 Vitamin B 6 Phase 3
41 Histamine H1 Antagonists, Non-Sedating Phase 3
42 topoisomerase I inhibitors Phase 2, Phase 3
43 Protein Kinase Inhibitors Phase 3
44 taxane Phase 3
45
Medroxyprogesterone Phase 3 520-85-4 10631
46 Progestins Phase 3
47 Tubulin Modulators Phase 3
48 Antimitotic Agents Phase 3
49 Cola Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 862)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study. Unknown status NCT00719017 Phase 4
2 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
3 Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer Completed NCT00190697 Phase 4 arzoxifene
4 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Recruiting NCT03349463 Phase 4 Fluciclovine F18
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Terminated NCT03423082 Phase 4 18F fluciclovine
7 A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Unknown status NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
8 Role Of Uterine Manipulator in Hysterectomy for Early Stage Endometrial Cancer Unknown status NCT02762214 Phase 3
9 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
10 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
11 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
12 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Unknown status NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
13 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
14 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
15 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
16 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
17 Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer Completed NCT03241914 Phase 2, Phase 3 Megestrol Acetate
18 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
19 PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy Completed NCT00376844 Phase 3
20 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
21 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
22 A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
23 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
24 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
25 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
26 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
27 A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial Completed NCT01470677 Phase 3 Tachosil fibrin patch
28 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
29 Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer. Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
30 LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial Completed NCT00096408 Phase 3
31 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
32 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
33 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
34 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
35 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
36 Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel Completed NCT04237090 Phase 3 Diphenhydramine;Cetirizine;Lactose pill;Sodium chloride 0.9%
37 Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer Recruiting NCT03603184 Phase 3 Atezolizumab;Placebos;Paclitaxel;Carboplatin
38 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
39 A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Recruiting NCT04214067 Phase 3
40 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
41 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Recruiting NCT04634877 Phase 3 Carboplatin;Paclitaxel;Placebo for pembrolizumab;Docetaxel;Cisplatin;Cisplatin (as radiosensitizer)
42 A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) Recruiting NCT04269200 Phase 3 olaparib;durvalumab placebo;olaparib placebo;Carboplatin;Paclitaxel
43 Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
44 Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer Recruiting NCT04705649 Phase 2, Phase 3
45 A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer Recruiting NCT03555422 Phase 3 Selinexor;Matching placebo for selinexor
46 A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer Recruiting NCT03785288 Phase 3
47 VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Recruiting NCT03324958 Phase 3
48 A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer Recruiting NCT04073706 Phase 3
49 Canadian Multi-arm Multi-stage Randomized Controlled Trial Assessing Front Line Treatment in Serous or p53 Mutant Endometrial Cancer Recruiting NCT04159155 Phase 2, Phase 3 Cisplatin;Carboplatin;Paclitaxel
50 Randomised Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Radiotherapy for Women With Early Stage Endometrial Cancer: PORTEC-4a Trial Recruiting NCT03469674 Phase 3

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carboplatin
Cyclophosphamide
Leuprolide
Leuprolide Acetate
Medroxyprogesterone
medroxyprogesterone acetate
Megestrol
Megestrol Acetate

Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 29 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 29

Anatomical Context for Endometrial Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

19
Tissues Lining The Uterus

MalaCards organs/tissues related to Endometrial Cancer:

40
Breast, Lymph Node, Uterus, Ovary, Cervix, Bone, Endothelial

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 23734)
# Title Authors PMID Year
1
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. 54 57 6 61
17525745 2007
2
Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. 61 6 57
17956577 2007
3
Drug-sensitive FGFR2 mutations in endometrial carcinoma. 54 57 61
18552176 2008
4
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. 61 54 57
10072435 1999
5
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. 6 61 54
8782829 1996
6
The mutational landscape of normal human endometrial epithelium. 61 57
32350471 2020
7
Integrated genomic characterization of endometrial carcinoma. 61 57
23636398 2013
8
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. 57 61
23104009 2012
9
Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer. 61 57
12872259 2003
10
Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. 61 6
9740666 1998
11
Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. 61 6
8980400 1996
12
Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. 6
27476653 2016
13
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
14
First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. 6
21815886 2011
15
Targeting mutant fibroblast growth factor receptors in cancer. 6
21367659 2011
16
MLH3 and EXO1 alterations in familial colorectal cancer patients not fulfilling Amsterdam criteria. 6
17656264 2007
17
Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene. 6
16440883 2005
18
Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis. 6
12900900 2003
19
The role of hMLH3 in familial colorectal cancer. 6
12702580 2003
20
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. 6
12588804 2003
21
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. 6
12606733 2003
22
Abnormal spliceform expression associated with splice acceptor mutations in exon IIIc of FGFR2. 6
12124745 2002
23
Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome. 6
12000365 2002
24
Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. 6
11818965 2002
25
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. 6
11390973 2001
26
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. 57
11418155 2001
27
Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly. 6
9719378 1998
28
A common mitochondrial DNA variant is associated with insulin resistance in adult life. 57
9498630 1998
29
PTEN1 is frequently mutated in primary endometrial carcinomas. 6
9326929 1997
30
Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. 6
8696350 1996
31
Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. 6
8651276 1996
32
Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. 6
7728760 1995
33
Mutations of the E-cadherin gene in human gynecologic cancers. 6
8075649 1994
34
Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. 61 54
19960433 2010
35
Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. 61 54
20087603 2010
36
Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis. 54 61
19446313 2010
37
IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. 61 54
20472848 2010
38
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. 61 54
20178884 2010
39
5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. 61 54
19306077 2010
40
Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). 61 54
20304627 2010
41
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. 61 54
20153885 2010
42
Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. 54 61
20053928 2010
43
The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. 61 54
20204292 2010
44
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. 54 61
20062086 2010
45
High density of peritumoral lymphatic vessels is a potential prognostic marker of endometrial carcinoma: a clinical immunohistochemical method study. 61 54
20374665 2010
46
Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. 54 61
20492382 2010
47
FGFR2 mutations are rare across histologic subtypes of ovarian cancer. 61 54
20106510 2010
48
Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. 54 61
20127022 2010
49
Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. 54 61
19756737 2010
50
Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. 54 61
20113256 2010

Variations for Endometrial Cancer

ClinVar genetic disease variations for Endometrial Cancer:

6 (show top 50) (show all 102)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MLH3 NM_014381.3(MLH3):c.885del (p.His296fs) Deletion Pathogenic 5563 rs1431264077 GRCh37: 14:75515474-75515474
GRCh38: 14:75048771-75048771
2 AREL1 , MLH3 NM_001040108.1(MLH3):c.2221G>T (p.Val741Phe) SNV Pathogenic 5561 rs28756990 GRCh37: 14:75514138-75514138
GRCh38: 14:75047435-75047435
3 PTEN NM_000314.7(PTEN):c.1012del (p.Ser338fs) Deletion Pathogenic 562182 rs1564568660 GRCh37: 10:89720858-89720858
GRCh38: 10:87961101-87961101
4 CDH1 NM_004360.5(CDH1):c.1147C>T (p.Gln383Ter) SNV Pathogenic 142888 rs587782798 GRCh37: 16:68847225-68847225
GRCh38: 16:68813322-68813322
5 MSH6 NM_000179.3(MSH6):c.3103C>T SNV Pathogenic 89338 rs63749999 GRCh37: 2:48028225-48028225
GRCh38: 2:47801086-47801086
6 MSH6 NM_000179.2(MSH6):c.3922_3940dup (p.Gln1314fs) Duplication Pathogenic 433928 rs1553333598 GRCh37: 2:48033710-48033711
GRCh38: 2:47806571-47806572
7 CDH1 NM_004360.5(CDH1):c.220C>T (p.Arg74Ter) SNV Pathogenic 239891 rs876658932 GRCh37: 16:68835629-68835629
GRCh38: 16:68801726-68801726
8 PTEN NM_000314.7(PTEN):c.253+1G>A SNV Pathogenic 7820 rs587776667 GRCh37: 10:89690847-89690847
GRCh38: 10:87931090-87931090
9 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) SNV Pathogenic 13277 rs121913478 GRCh37: 10:123274794-123274794
GRCh38: 10:121515280-121515280
10 MSH6 NM_000179.3(MSH6):c.3439-2A>G SNV Pathogenic 89391 rs267608098 GRCh37: 2:48032047-48032047
GRCh38: 2:47804908-47804908
11 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Pathogenic 13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
12 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Pathogenic 375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
13 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys) SNV Pathogenic 5293 rs34612342 GRCh37: 1:45798475-45798475
GRCh38: 1:45332803-45332803
14 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp) SNV Pathogenic 5294 rs36053993 GRCh37: 1:45797228-45797228
GRCh38: 1:45331556-45331556
15 CDH1 NM_004360.5(CDH1):c.2131C>G (p.Leu711Val) SNV Pathogenic 12231 rs121964871 GRCh37: 16:68857496-68857496
GRCh38: 16:68823593-68823593
16 CDH1 NM_004360.5(CDH1):c.1849G>A (p.Ala617Thr) SNV Pathogenic 12232 rs33935154 GRCh37: 16:68856041-68856041
GRCh38: 16:68822138-68822138
17 MSH6 NM_000179.3(MSH6):c.10C>T (p.Gln4Ter) SNV Pathogenic 183723 rs786201042 GRCh37: 2:48010382-48010382
GRCh38: 2:47783243-47783243
18 MSH6 NM_000179.2(MSH6):c.2731C>T (p.Arg911Ter) SNV Pathogenic 89312 rs63751017 GRCh37: 2:48027853-48027853
GRCh38: 2:47800714-47800714
19 MSH3 NM_002439.5(MSH3):c.1148del (p.Lys383fs) Deletion Pathogenic 8738 rs587776701 GRCh37: 5:79970915-79970915
GRCh38: 5:80675096-80675096
20 MSH6 NM_000179.2(MSH6):c.2731C>T (p.Arg911Ter) SNV Pathogenic 89312 rs63751017 GRCh37: 2:48027853-48027853
GRCh38: 2:47800714-47800714
21 MSH6 NM_000179.3(MSH6):c.3202C>T SNV Pathogenic 89352 rs63749843 GRCh37: 2:48030588-48030588
GRCh38: 2:47803449-47803449
22 MSH6 NM_000179.3(MSH6):c.3202C>T SNV Pathogenic 89352 rs63749843 GRCh37: 2:48030588-48030588
GRCh38: 2:47803449-47803449
23 CTNNB1 NM_001904.4(CTNNB1):c.95A>T (p.Asp32Val) SNV Likely pathogenic 376230 rs121913396 GRCh37: 3:41266098-41266098
GRCh38: 3:41224607-41224607
24 FGFR2 NM_000141.5(FGFR2):c.1914T>A (p.Asn638Lys) SNV Likely pathogenic 376315 rs1057519854 GRCh37: 10:123247577-123247577
GRCh38: 10:121488063-121488063
25 FGFR2 NM_000141.5(FGFR2):c.1642A>C (p.Ile548Leu) SNV Likely pathogenic 376433 rs1057519901 GRCh37: 10:123258039-123258039
GRCh38: 10:121498525-121498525
26 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp) SNV Likely pathogenic 13272 rs79184941 GRCh37: 10:123279677-123279677
GRCh38: 10:121520163-121520163
27 CTNNB1 NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr) SNV Likely pathogenic 17577 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
28 CTNNB1 NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn) SNV Likely pathogenic 376228 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606
29 overlap with 54 genes inv(2)(p21p23.2) Inversion Likely pathogenic 547174 GRCh37: 2:29447680-42554394
GRCh38:
30 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys) SNV Likely pathogenic 13277 rs121913478 GRCh37: 10:123274794-123274794
GRCh38: 10:121515280-121515280
31 overlap with 3 genes NC_000004.11:g.1737488_1808653dup Duplication Likely pathogenic 495323 GRCh37: 4:1737488-1808653
GRCh38: 4:1735761-1806926
32 MSH6 NM_000179.2(MSH6):c.3801+1G>T SNV Likely pathogenic 234228 rs876660943 GRCh37: 2:48033498-48033498
GRCh38: 2:47806359-47806359
33 FGFR2 NM_000141.5(FGFR2):c.1115C>G (p.Ser372Cys) SNV Likely pathogenic 13278 rs121913477 GRCh37: 10:123274803-123274803
GRCh38: 10:121515289-121515289
34 FGFR2 NM_000141.5(FGFR2):c.1141T>C (p.Tyr381His) SNV Likely pathogenic 376316 rs387906678 GRCh37: 10:123274777-123274777
GRCh38: 10:121515263-121515263
35 PIK3CA NM_006218.4(PIK3CA):c.3074C>G (p.Thr1025Ser) SNV Likely pathogenic 495324 rs1553826166 GRCh37: 3:178952019-178952019
GRCh38: 3:179234231-179234231
36 FGFR2 NM_000141.5(FGFR2):c.1121A>G (p.Asp374Gly) SNV Likely pathogenic 376726 rs1057520028 GRCh37: 10:123274797-123274797
GRCh38: 10:121515283-121515283
37 FGFR2 NM_000141.5(FGFR2):c.1974A>T (p.Lys658Asn) SNV Likely pathogenic 376727 rs1057520029 GRCh37: 10:123247517-123247517
GRCh38: 10:121488003-121488003
38 FGFR2 NM_000141.5(FGFR2):c.929A>G (p.Lys310Arg) SNV Likely pathogenic 376317 rs121913475 GRCh37: 10:123279503-123279503
GRCh38: 10:121519989-121519989
39 FGFR2 NM_000141.5(FGFR2):c.1972A>G (p.Lys658Glu) SNV Likely pathogenic 376725 rs1057520027 GRCh37: 10:123247519-123247519
GRCh38: 10:121488005-121488005
40 overlap with 26 genes NC_000016.9:g.2127606_2334390dup Duplication Uncertain significance 495325 GRCh37: 16:2127606-2334390
GRCh38: 16:2077605-2284389
41 MLH3 NM_001040108.1(MLH3):c.2911G>A (p.Val971Ile) SNV Uncertain significance 410896 rs41555714 GRCh37: 14:75513448-75513448
GRCh38: 14:75046745-75046745
42 MSH6 NM_000179.3(MSH6):c.3259C>T (p.Pro1087Ser) SNV Uncertain significance 89360 rs63750998 GRCh37: 2:48030645-48030645
GRCh38: 2:47803506-47803506
43 MSH6 NM_000179.3(MSH6):c.3260C>G (p.Pro1087Arg) SNV Uncertain significance 89362 rs63750753 GRCh37: 2:48030646-48030646
GRCh38: 2:47803507-47803507
44 MSH6 NM_000179.2(MSH6):c.3605T>C (p.Met1202Thr) SNV Uncertain significance 89424 rs587779273 GRCh37: 2:48032805-48032805
GRCh38: 2:47805666-47805666
45 MSH6 NM_000179.2(MSH6):c.3788G>A (p.Arg1263His) SNV Uncertain significance 127593 rs147852216 GRCh37: 2:48033484-48033484
GRCh38: 2:47806345-47806345
46 MSH6 NM_000179.2(MSH6):c.3919A>C (p.Asn1307His) SNV Uncertain significance 182649 rs730881808 GRCh37: 2:48033708-48033708
GRCh38: 2:47806569-47806569
47 CDH1 NM_004360.5(CDH1):c.1250A>G (p.Asn417Ser) SNV Uncertain significance 185286 rs773441320 GRCh37: 16:68847328-68847328
GRCh38: 16:68813425-68813425
48 CDH1 NM_004360.5(CDH1):c.1774G>T (p.Ala592Ser) SNV Uncertain significance 184624 rs35187787 GRCh37: 16:68855966-68855966
GRCh38: 16:68822063-68822063
49 MSH6 NM_000179.3(MSH6):c.73G>T (p.Ala25Ser) SNV Uncertain significance 89562 rs267608026 GRCh37: 2:48010445-48010445
GRCh38: 2:47783306-47783306
50 MSH6 NM_000179.2(MSH6):c.104C>T (p.Ala35Val) SNV Uncertain significance 410435 rs776547943 GRCh37: 2:48010476-48010476
GRCh38: 2:47783337-47783337

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

72
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 47039)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264503 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 24
2 COSM88264271 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 24
3 COSM88264495 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 24
4 COSM87271104 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 24
5 COSM87278520 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8029G>A p.E2677K 16:72794653-72794653 24
6 COSM102036325 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.762G>T p.E254D 16:72829804-72829804 24
7 COSM87274708 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 24
8 COSM87281210 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4072T>G p.S1358A 16:72798610-72798610 24
9 COSM87291966 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 24
10 COSM102036916 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3865C>T p.R1289C 16:72796075-72796075 24
11 COSM149332944 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 24
12 COSM87284078 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 24
13 COSM149265473 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8512G>A p.V2838I 16:72794170-72794170 24
14 COSM87289878 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 24
15 COSM102020191 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1387C>A p.L463I 16:72798553-72798553 24
16 COSM149320029 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 24
17 COSM149276742 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1753G>A p.G585S 16:72958393-72958393 24
18 COSM87277220 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 24
19 COSM87275783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1411G>A p.E471K 16:72958735-72958735 24
20 COSM102020207 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4078C>T p.Q1360* 16:72795862-72795862 24
21 COSM102043844 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6219G>T p.K2073N 16:72793721-72793721 24
22 COSM149319798 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 24
23 COSM149259590 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1936G>A p.D646N 16:72958210-72958210 24
24 COSM87271751 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 24
25 COSM102042266 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8224C>T p.P2742S 16:72787310-72787310 24
26 COSM149286811 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 24
27 COSM149314151 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 24
28 COSM149261368 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4342C>A p.L1448I 16:72798340-72798340 24
29 COSM87283861 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3271G>A p.V1091I 16:72889908-72889908 24
30 COSM87292093 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2459G>A p.R820H 16:72957687-72957687 24
31 COSM102022012 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1832T>C p.L611P 16:72798108-72798108 24
32 COSM149284453 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4653G>T p.K1551N 16:72798029-72798029 24
33 COSM87278783 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 24
34 COSM87292968 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 24
35 COSM102043873 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.655G>A p.E219K 16:72889782-72889782 24
36 COSM102036330 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-7212G>A p.? 16:72958177-72958177 24
37 COSM149265910 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 24
38 COSM149292038 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8633C>T p.A2878V 16:72794049-72794049 24
39 COSM149293431 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 24
40 COSM149281700 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8617G>A p.E2873K 16:72794065-72794065 24
41 COSM87293150 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3193G>A p.E1065K 16:72950492-72950492 24
42 COSM87289627 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 24
43 COSM87285871 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 24
44 COSM102045840 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.-23-9018G>A p.? 16:72959983-72959983 24
45 COSM149322559 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2861C>T p.T954M 16:72950824-72950824 24
46 COSM87293131 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8961G>T p.K2987N 16:72793721-72793721 24
47 COSM149264593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.629G>A p.G210D 16:72959517-72959517 24
48 COSM102023623 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1183C>T p.R395* 16:72800069-72800069 24
49 COSM149261344 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 24
50 COSM149280950 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 24

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Endometrial cancer hsa05213

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 PTEN MSH6 MSH3 FGFR2 CDH1
2 12.08 PTEN MSH6 MSH3 FGFR2 CDH1
3
Show member pathways
11.41 MSH6 MSH3 MLH3
4 9.88 UCA1 LINC-ROR HOTAIR

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.8 MSH6 MSH3 MLH3

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of DNA recombination GO:0045910 9.37 MSH6 MSH3
2 positive regulation of helicase activity GO:0051096 9.32 MSH6 MSH3
3 maintenance of DNA repeat elements GO:0043570 9.26 MSH6 MSH3
4 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MSH6 MSH3
5 meiotic mismatch repair GO:0000710 8.96 MSH6 MSH3
6 mismatch repair GO:0006298 8.92 MUTYH MSH6 MSH3 MLH3

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex binding GO:0032405 9.32 MUTYH MSH6
2 guanine/thymine mispair binding GO:0032137 9.26 MSH6 MSH3
3 single guanine insertion binding GO:0032142 9.16 MSH6 MSH3
4 mismatched DNA binding GO:0030983 9.13 MSH6 MSH3 MLH3
5 oxidized purine DNA binding GO:0032357 8.8 MUTYH MSH6 MSH3

Sources for Endometrial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....